AKBA
Akebia Therapeutics Inc
NASDAQ · Biotechnology
$1.39
+0.01 (+0.72%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 72.37M | 65.59M | 81.13M |
| Net Income | -4,487,469 | -3,878,355 | -4,942,326 |
| EPS | — | — | — |
| Profit Margin | -6.2% | -5.9% | -6.1% |
| Rev Growth | -8.8% | +11.6% | -8.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 27.55M | 21.85M | 26.69M |
| Total Equity | 130.26M | 127.43M | 136.15M |
| D/E Ratio | 0.21 | 0.17 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -4,274,433 | -4,128,349 | -4,627,733 |
| Free Cash Flow | -2,482,756 | -1,979,346 | -2,914,255 |